Axience SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Axience SAS - overview
Established
2001
Location
Pantin, -, France
Primary Industry
Pharmaceuticals
About
Founded in 2001 and based in Pantin, France, Axience SAS operates in the animal health sector. It markets veterinary products, such as medicines, dietary food supplements, and hygiene and disinfection products, intended for pets and livestock. In February 2024, Motion Equity Partners acquired Axience SAS. The company offers a range of veterinary pharmaceuticals, including both proprietary and generic medications, as well as hygiene and disinfection products for veterinary clinics, targeting pets, equines, bovines, and swine.
The company also specializes in anesthesia and analgesia products for various animal species.
Current Investors
Motion Equity Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.axience.fr
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Axience SAS - timeline of key events
Axience SAS - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 12,051,861 | 12,028,669 | 13,440,176 | 10,951,027 | 12,505,629 | 15,151,914 | - | - | - |
| % Revenue Growth (YoY) | - | (0.2%) | 11.7% | (18.5%) | 14.2% | 21.2% | - | - | - |
| EBITDA (USD) | 1,359,611 | 1,557,724 | 1,684,279 | 445,282 | 780,551 | 1,420,887 | - | - | - |
| Operating Income (USD) | 1,341,238 | 1,540,699 | 1,657,276 | 401,957 | 689,957 | 1,247,165 | - | - | - |
| Operating Margin | 11.1% | 12.8% | 12.3% | 3.7% | 5.5% | 8.2% | - | - | - |
| % EBITDA Margin | 11.3% | 13.0% | 12.5% | 4.1% | 6.2% | 9.4% | - | - | - |
| NET Income (USD) | 497,620 | 798,575 | 606,563 | 36,630 | 230,826 | 195,074 | - | - | - |
| % Net Margin | 4.1% | 6.6% | 4.5% | 0.3% | 1.8% | 1.3% | - | - | - |
Axience SAS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Axience SAS | - |
Displaying 1 - 1 of 1
Axience SAS - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.